The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. Separately, Cogentus has begun Cogent-1, a global Phase III trial that will evaluate the clinical benefits of CGT-2168 with aspirin compared to Plavix with aspirin.
Mark Goldsmith, chairman and CEO of Cogentus, said: “We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today.”